Stockscreener 앱 받기
32.25
4.73%
-1.60
전일 마감가:
$33.85
열려 있는:
$34.13
하루 거래량:
6.24M
Relative Volume:
3.26
시가총액:
$19.87B
수익:
$2.62B
순이익/손실:
$966.70M
주가수익비율:
21.49
EPS:
1.5004
순현금흐름:
$1.09B
1주 성능:
-5.87%
1개월 성능:
+2.87%
6개월 성능:
+47.46%
1년 성능:
+51.98%
1일 변동 폭
$30.88
$34.24
1주일 범위
$30.88
$35.43
52주 변동 폭
$17.23
$35.43
Genmab Adr Stock (GMAB) Company Profile
GMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
32.25 | 20.85B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-04-01 | 다운그레이드 | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-04 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-08-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-12-06 | 업그레이드 | UBS | Neutral → Buy |
| 2023-11-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-11-08 | 업그레이드 | DNB Markets | Sell → Buy |
| 2023-10-18 | 개시 | Exane BNP Paribas | Underperform |
| 2023-09-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 개시 | BTIG Research | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-31 | 개시 | UBS | Neutral |
| 2023-05-12 | 개시 | Morgan Stanley | Underweight |
| 2022-12-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-11-14 | 개시 | William Blair | Mkt Perform |
| 2022-11-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 개시 | BMO Capital Markets | Market Perform |
| 2022-05-02 | 개시 | Cowen | Market Perform |
| 2022-03-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-12-01 | 개시 | Berenberg | Sell |
| 2021-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 개시 | Deutsche Bank | Buy |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | 다운그레이드 | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 개시 | SVB Leerink | Mkt Perform |
| 2020-06-25 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 개시 | Credit Suisse | Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-12 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-09-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | Morgan Stanley | Overweight |
| 2019-08-12 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Genmab Adr 주식(GMAB)의 최신 뉴스
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - GlobeNewswire Inc.
Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN
Genmab A/S (GMAB): A Bull Case Theory - Finviz
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Eagle Global Advisors LLC Buys 34,175 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Genmab A/S (NASDAQ:GMAB) Hits New 52-Week HighTime to Buy? - MarketBeat
Genmab A/S (OTCMKTS:GNMSF) Reaches New 1-Year HighShould You Buy? - MarketBeat
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN
Quoin Pharm ADR clears technical benchmark, hitting 90-plus RS rating - MSN
Genmab A/SAmerican Depositary Shares (NQ: GMAB - FinancialContent
Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week HighHere's What Happened - MarketBeat
Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN
Genmab A/S (NASDAQ:GMAB) Shares Down 3.5% – Here’s Why - Defense World
Genmab A/S (NASDAQ:GMAB) Stock Price Down 3.5%Time to Sell? - MarketBeat
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus - TechStock²
Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab Portfolio Prioritization Update - GlobeNewswire
Genmab–BioNTech cancer antibody trial ends early: What investors need to know - MSN
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know - TipRanks
Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year HighStill a Buy? - MarketBeat
Squarepoint Ops LLC Has $1.95 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
China Universal Asset Management Co. Ltd. Has $381,000 Stake in Genmab A/S Sponsored ADR $GMAB - Defense World
The 5 Best Stocks To Buy And Watch Right Now - Investor's Business Daily
Pipeline of Proprietary Antibodies - flow – Deutsche Bank
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 86,842 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by First Trust Advisors LP - Defense World
Quoin Pharm ADR Joins Rank Of Stocks With RS Ratings Over 90 - MSN
Dow Jones Stock Caterpillar In Buy Zone After Recent Breakout Move - Investor's Business Daily
Marshall Wace LLP Cuts Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by American Century Companies Inc. - Defense World
AI Plays Lead Five Stocks To Watch Near Buy Points - Investor's Business Daily
Arrowstreet Capital Limited Partnership Raises Position in Genmab A/S Sponsored ADR $GMAB - Defense World
JPMorgan Chase & Co. Grows Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Dow Jones Futures Rise; Netflix To Buy Warner Bros - Investor's Business Daily
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter - Investor's Business Daily
Genmab A/S Sponsored ADR $GMAB Position Reduced by Russell Investments Group Ltd. - MarketBeat
Capital Fund Management S.A. Has $4.68 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arbor Realty Trust Inc (ABR): What is the Risk Factor? - fostersleader.com
Level Four Advisory Services LLC Acquires 12,888 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR Earns Membership In 95-Plus Composite Rating Club - MSN
Rockefeller Capital Management L.P. Purchases New Shares in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab Adr (GMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Genmab Adr 주식 (GMAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
2,978 |
288,866 |
72,831,487 |
| GENMAB A/S | 10% Owner |
Dec 23 '25 |
Buy |
97.00 |
561,042 |
54,421,074 |
72,589,817 |
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
142,610 |
13,833,170 |
72,828,509 |
| GENMAB A/S | 10% Owner |
Dec 24 '25 |
Buy |
97.00 |
96,082 |
9,319,954 |
72,685,899 |
| GENMAB A/S | 10% Owner |
Dec 22 '25 |
Buy |
97.00 |
15,710 |
1,523,870 |
72,028,775 |
| GENMAB A/S | 10% Owner |
Dec 18 '25 |
Buy |
97.00 |
212,177 |
20,581,169 |
71,946,801 |
| GENMAB A/S | 10% Owner |
Dec 19 '25 |
Buy |
97.00 |
66,264 |
6,427,608 |
72,013,065 |
| GENMAB A/S | 10% Owner |
Dec 17 '25 |
Buy |
97.00 |
150,795 |
14,627,115 |
71,734,624 |
| GENMAB A/S | 10% Owner |
Dec 16 '25 |
Buy |
97.00 |
120,752 |
11,712,944 |
71,583,829 |
0.92%
2.43%
자본화:
|
볼륨(24시간):